| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| host | rabbit |
| isotype | IgG |
| clonality | polyclonal |
| concentration | 1 mg/mL |
| applications | ICC/IF, WB |
| reactivity | MyD88 (CT) |
| available sizes | 100 µg |
rabbit anti-MyD88 (CT) polyclonal antibody 7237
$445.00
Antibody summary
- Rabbit polyclonal to MyD88 (CT)
- Suitable for: ELISA,WB,IF,IP
- Isotype: IgG
- 100 µg
rabbit anti-MyD88 (CT) polyclonal antibody 7237
| antibody |
|---|
| Tested applications WB,IHC,IHC,ICC/IF,ELISA |
| Recommended dilutions Immunoblotting: use at 1:500-1:1,000 dilution. Positive control: Whole cell lysate from Jurkat cells. |
| Immunogen Peptide corresponding to aa 279-296 of human MyD88. The sequence is identical to that of mouse MyD88. |
| Size and concentration 100µg and lot specific |
| Form liquid |
| Storage Instructions This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze- thaw cycles. |
| Storage buffer PBS, pH 7.4. |
| Purity peptide affinty purifcation |
| Clonality polyclonal |
| Isotype IgG |
| Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720 |
| Isotype control Rabbit polyclonal - Isotype Control |
| target relevance |
|---|
| Protein names Myeloid differentiation primary response protein MyD88 |
| Gene names MYD88,MYD88 |
| Mass 33233Da |
| Function FUNCTION: Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response (PubMed:15361868, PubMed:18292575, PubMed:33718825). Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:15361868, PubMed:24316379, PubMed:19506249). Increases IL-8 transcription (PubMed:9013863). Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Upon TLR8 activation by GU-rich single-stranded RNA (GU-rich RNA) derived from viruses such as SARS-CoV-2, SARS-CoV and HIV-1, induces IL1B release through NLRP3 inflammasome activation (PubMed:33718825). MyD88-mediated signaling in intestinal epithelial cells is crucial for maintenance of gut homeostasis and controls the expression of the antimicrobial lectin REG3G in the small intestine (By similarity). {ECO:0000250|UniProtKB:P22366, ECO:0000269|PubMed:15361868, ECO:0000269|PubMed:18292575, ECO:0000269|PubMed:19506249, ECO:0000269|PubMed:20855887, ECO:0000269|PubMed:24316379, ECO:0000269|PubMed:33718825, ECO:0000269|PubMed:9013863}. |
| Subellular location SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15361868, ECO:0000269|PubMed:15492225}. Nucleus {ECO:0000269|PubMed:21057262}. |
| Tissues TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:8957090}. |
| Structure SUBUNIT: Homodimer. Also forms heterodimers with TIRAP (PubMed:17322885, PubMed:19948740, PubMed:19506249). Binds to TLR2, TLR5, IRAK1, IRAK2 and IRAK4 via their respective TIR domains. Interacts with IL18R1. Interacts with BMX, IL1RL1, IKBKE and IRF7. Interacts with LRRFIP1 and LRRFIP2; this interaction positively regulates Toll-like receptor (TLR) signaling in response to agonist. Interacts with FLII. LRRFIP1 and LRRFIP2 compete with FLII for MYD88-binding. Interacts with IRF1. Upon IL1B treatment, forms a complex with PELI1, IRAK1, IRAK4 and TRAF6; this complex recruits MAP3K7/TAK1, TAB1 and TAB2 to mediate NF-kappa-B activation. Direct binding of SMAD6 to PELI1 prevents the complex formation and hence negatively regulates IL1R-TLR signaling and eventually NF-kappa-B-mediated gene expression. May interact with PIK3AP1. Interacts (via TIR domain) with DHX9 (via H2A and OB-fold regions); this interaction is direct (PubMed:20696886). Interacts with OTUD4 deubiquitinase; the interaction is direct (PubMed:29395066). Interacts with TLR4 (PubMed:36232715). {ECO:0000269|PubMed:15361868, ECO:0000269|PubMed:15492225, ECO:0000269|PubMed:16286016, ECO:0000269|PubMed:16951688, ECO:0000269|PubMed:17322885, ECO:0000269|PubMed:18292575, ECO:0000269|PubMed:19265123, ECO:0000269|PubMed:19506249, ECO:0000269|PubMed:19948740, ECO:0000269|PubMed:20696886, ECO:0000269|PubMed:20855887, ECO:0000269|PubMed:20966070, ECO:0000269|PubMed:21179087, ECO:0000269|PubMed:23453969, ECO:0000269|PubMed:24316379, ECO:0000269|PubMed:29395066, ECO:0000269|PubMed:36232715}.; SUBUNIT: (Microbial infection) In case of infection, interacts with uropathogenic E.coli protein TcpC; suppressing Toll-like receptor (TLR)-mediated cytokine production. {ECO:0000269|PubMed:23569230}.; SUBUNIT: (Microbial infection) In case of infection, interacts with uropathogenic E.faecalis protein TcpF; suppressing Toll-like receptor (TLR)-mediated cytokine production. {ECO:0000269|PubMed:25369374}.; SUBUNIT: (Microbial infection) In case of infection, interacts with B.melitensis protein TcpB. {ECO:0000269|PubMed:22155231, ECO:0000269|PubMed:24265315}.; SUBUNIT: (Microbial infection) Interacts with human metapneumovirus protein M2-2; this interaction prevents MYD88-mediated cytokine secretion. {ECO:0000269|PubMed:24618691}. |
| Post-translational modification PTM: Ubiquitinated; undergoes 'Lys-63'-linked polyubiquitination. OTUD4 specifically hydrolyzes 'Lys-63'-linked polyubiquitinated MYD88. {ECO:0000269|PubMed:29395066}. |
| Target Relevance information above includes information from UniProt accession : Q99836 |
| The UniProt Consortium |
Data
 |
| KO Validation in HeLa Cells Loading: 10 µg of HeLa WT cell lysate or MyD88 KO cell lysate. Antibodies: MyD88 7237 (2 µg/mL) and beta-actin 3779 (1 µg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution. |
 |
| Western Blot Validation of MyD88 in human cell lines Loading: 15 µg of lysates per lane. Antibodies: 7237 (2 µg/mL) 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Predicted band size: 35 kDa |
 |
| Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines Loading: 15 µg of lysates per lane. Antibodies: MyD88 2125 (2 µg/mL), MyD88 7237 (2 µg/mL), beta-actin (1 µg/mL), and GAPDH (0.02 µg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |
 |
| Independent Antibody Validation (IAV) via Protein Expression Profile in Human Tissues Loading: 15 µg of lysates per lane. Antibodies: MyD88 2125 (2 µg/mL), MyD88 7237 (2 µg/mL), beta-actin (1 µg/mL), and GAPDH (0.02 µg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |
 |
| Animal Species Reactivity Loading: Lysates/proteins at 15 µg per lane. Antibodies: 2125 (2 µg/mL) or 7237 (2 µg/mL). 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |
 |
| Immunofluorescence Validation of MyD88 in Jurkat Cells Immunofluorescent analysis of 4% paraformaldehyde-fixed Jurkat cells labeling MyD88 with 7237 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). |
 |
| Immunofluorescence Validation of MyD88 in K562 Cells Immunofluorescent analysis of 4% paraformaldehyde-fixed K562 cells labeling MyD88 with 7237 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). |
 |
| KO Validation of MyD88 in Mouse T cells (Rahman et al., 2011) Splenocytes were isolated from a ;Myd88ΔT ;mouse in which MyD88 was specifically disrupted in T cells. T and B cells were FACS purified, and MyD88 expression was examined by Western blot with anti-MyD88 antibodies (7237). MyD88 expression was detected in Splenocytes and B cells, but not in T cells. |
 |
| KO Validation in CD45 - Thy1 + cells (Kim et al., 2017) The expression of Myd88 protein was analyzed in CD45 - Thy1 + intestinal mesenchymal cells and CD3 + intestinalT cells, by immunoblotting with anti-Myd88 antibodies (7237). MyD88 expression was not detected in knockout cells. |
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.| pmid | title | authors | citation |
|---|
Protocols
| relevant to this product |
|---|
| Western blot IHC ICC |
Documents
| # | |||
|---|---|---|---|
| No results found | |||
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.